공고 • Jun 09

Innovent Biologics Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity and Metabolic Pipeline

Innovent Biologics presented multiple clinical and preclinical results of its innovative metabolic and obesity pipeline at the 2026 American Diabetes Association's Scientific Sessions. This includes three clinical oral presentations of mazdutide (GCG/GLP-1 dual agonist) across adults with type 2 diabetes and obesity, adults with obesity and adolescents with obesity, as well as preclinical data from its IBI3032 and IBI3042, as next-generation oral daily and weekly GLP-1 receptor agonists, along with IBI3040 (a novel amylin analog) and IBI3046 (an INHBE-targeting siRNA). IBI3032 is a novel, orally bioavailable non-peptidic GLP-1R agonist discovered via structure-based design, and has now advanced into Phase 1 clinical trials in both China and the United States. IBI3032 exhibited potent activation of the human GLP-1R (EC50 = 0.53 nM) with high selectivity and minimal ß-arrestin recruitment. IBI3032 demonstrated favorable cross-species pharmacokinetics and a robust preclinical efficacy profile. Pharmacokinetic studies revealed high oral exposure in cynomolgus monkeys, with a bioavailability of 24.5% and a half-life of 6.3 hours. Importantly, compared to the marketed small-molecule GLP-1R agonist Orforglipron, IBI3032 demonstrates significantly superior weight-loss efficiency—achieving markedly greater body weight loss at half of the dose in preclinical models. In a 28-day study in hGLP-1R knock-in DIO mice, oral IBI3032 produced dose-dependent body weight loss relative to vehicle (1 mg/kg: -1.8%; 6 mg/kg: -8.0%; 12 mg/kg: -10.8%). In a 28-day cynomolgus monkey study, once-daily oral administration of IBI3032 (1 mg/kg) produced 11.2% body weight loss versus vehicle. This differentiated profile supports its potential as a best-in-class oral therapy. Collectively, these findings underscore IBI3032 as a next-generation oral GLP-1R agonist that combines true oral convenience, low-dose efficacy, and accelerated global clinical development. Preclinical studies indicate IBI3032 has a higher oral exposure than other marketed oral small-molecule GLP-1 in cynomolgus monkeys and shows encouraging efficacy signals for weight loss in obese cynomolgus monkeys. Based on these preclinical findings, two Phase 1 studies were designed to preliminarily assess the human dose range, weight-loss efficacy signals, and safety and tolerability of IBI3032, further validate the hypothesis of potent weight loss at low doses, and provide key data to inform the subsequent clinical trial design. The single-ascending dose (SAD) study recruited 40 eligible participants with/without overweight or obesity (BMI 20–40 kg/m²) to receive once-daily single doses of IBI3032 at 0.3 mg, 1.0 mg, 3.0 mg and 6.0 mg. The multiple-ascending dose (MAD) study recruited a total of 79 overweight/obese participants (BMI 24–40 kg/m²) to receive once-daily oral IBI3032 for 4 weeks per protocol-specified dose titration ranging from 0.6 mg to 10 mg, aiming to evaluate multiple dose-escalation titration regimens. After a single oral dose, IBI3032's systemic exposure (AUCinf and Cmax) increased in an approximately dose-proportional manner across 0.3–6 mg dose range; peak plasma concentration (Tmax) occurred 5–12 hours post-dose. Its terminal elimination half-life is (T1/2) approximately 2 days, which supports a once-daily dosing regimen. Pharmacokinetics (PK) parameters after 4 weeks of sequential titration in MAD were consistent with SAD and exhibited linear PK characteristics. IBI3032 showed a manageable safety profile in both SAD and MAD studies; nearly all treatment-emergent adverse events were mild to moderate, with no treatment-related serious adverse events reported. No cases of acute pancreatitis, acute kidney injury, acute gallbladder disease, major adverse cardiovascular events, thyroid C-cell hyperplasia or thyroid carcinoma were reported in either study. Four-week cohort comparisons within MAD study demonstrated that low starting dose with stepwise dose escalation enables substantial weight reduction alongside meaningful improvement in gastrointestinal tolerability. In the cohort starting at 0.6 mg with seven-step escalation to 9 mg (n=12), 4-week treatment led to an average 10.11% body weight reduction after 4 weeks, while vomiting incidence remained at 8.3%. Compared with other cohorts utilizing the aggressive escalation approach with high starting doses and large dose increments, this slow titration regimen with lower initial dose, smaller incremental jumps and prolonged escalation cycle lowers gastrointestinal adverse event risk while retaining weight-lowering efficacy, providing evidence for future clinical dosing regimen development. Additional Phase 1 clinical study of IBI3032 is ongoing to further explore and refine optimal dose titration schemes. IBI3040 is a highly potent agonist of the amylin and calcitonin (CTR) receptors. In a 2-week study in DIO rats, IBI3040 at 2 and 10 nmol/kg Third Quarter resulted in dose-dependent reductions in body weight of 8.82% and 11.11%, respectively, compared to vehicle-treated rats. In another study, the combination of IBI3040 and semaglutide resulted in a greater weight reduction of -14.7%, whereas monotherapy with IBI3040 or semaglutide produced weight losses of -10.12% and -3.01% in DIO rats, respectively, indicating an additive effect of the combined treatment. Compared to cagrilintide, IBI3040 displays a favorable PK profile, high solubility, and stability without fibril formation at physiological pH (7-8). IBI3040 demonstrates superior receptor activation, robust weight loss effects compared to cargrilintide and eloralintide, and synergistic potential with semaglutide, supporting its development as a next-generation amylin analog for obesity treatment. IBI3042 is potentially the world's first once-weekly oral small-molecule GLP-1 receptor agonist candidate entering clinical studies by the end of 2026. The weekly dosing potential is offering a compelling new option for patients seeking a more convenient and manageable long-term treatment for type 2 diabetes and obesity. IBI3042 exhibited GLP-1R activation in cAMP assays, but showed no ß-arrestin recruitment in NanoBiT assays. In human GLP-1 receptor knock-in (GLP-1R KI) mice, IBI3042 (0.4 mg/kg P.O.) maintained significant glucose-lowering effects for at least 7 days, outperforming Orforglipron at the same dose. In diet-induced obese (DIO) humanized GLP-1 receptor knock-in mice, IBI3042 at 1 mg/kg twice weekly showed comparable efficacy to Orforglipron 1.5 mg/kg once daily, while the 3 mg/kg twice-weekly dose demonstrated superior efficacy. In contrast, Orforglipron at 3 mg/kg twice weekly showed no notable efficacy. In obese cynomolgus monkeys, IBI3042 produced robust, dose-dependent body weight reduction with twice-weekly oral dosing (1.5–4.5 mg/kg).

Biotechs 이익 성장	24.4%
매출 성장률	19.5%
향후 자기자본이익률	16.09%
애널리스트 커버리지	Good
마지막 업데이트	15 Jul 2026

날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	26,571	4,678	4,641	5,466	24
12/31/2027	22,181	3,340	3,454	3,998	27
12/31/2026	18,558	2,015	3,392	2,906	27
12/31/2025	13,042	814	9,318	10,001	N/A
9/30/2025	12,232	973	4,981	5,909	N/A
6/30/2025	11,423	1,132	644	1,816	N/A
3/31/2025	10,422	519	145	1,552	N/A
12/31/2024	9,422	-95	-355	1,287	N/A
9/30/2024	8,439	-688	-662	921	N/A
6/30/2024	7,457	-1,281	-969	555	N/A
3/31/2024	6,831	-1,155	-1,102	351	N/A
12/31/2023	6,206	-1,028	-1,234	148	N/A
9/30/2023	5,612	-1,198	-2,241	-794	N/A
6/30/2023	5,018	-1,368	-3,249	-1,735	N/A
3/31/2023	4,787	-1,774	-3,267	-1,827	N/A
12/31/2022	4,556	-2,179	-3,284	-1,919	N/A
9/30/2022	4,562	-2,427	-3,507	-1,867	N/A
6/30/2022	4,568	-2,676	-3,729	-1,816	N/A
3/31/2022	4,419	-2,702	-3,801	-1,920	N/A
12/31/2021	4,270	-2,729	-3,872	-2,025	N/A
9/30/2021	4,536	-2,061	-2,660	-1,302	N/A
6/30/2021	4,801	-1,394	-1,447	-580	N/A
3/31/2021	4,323	-1,196	-1,138	-444	N/A
12/31/2020	3,844	-998	-829	-308	N/A
9/30/2020	2,765	-1,306	-1,307	-900	N/A
6/30/2020	1,686	-1,614	-1,784	-1,492	N/A
3/31/2020	1,367	-1,667	-1,907	-1,578	N/A
12/31/2019	1,048	-1,720	-2,030	-1,664	N/A
9/30/2019	699	-4,125	N/A	-1,625	N/A
6/30/2019	351	-6,530	N/A	-1,586	N/A
3/31/2019	180	-6,151	N/A	-1,299	N/A
12/31/2018	9	-5,771	N/A	-1,012	N/A
9/30/2018	39	-3,041	N/A	-799	N/A
6/30/2018	69	-311	N/A	-587	N/A
3/31/2018	72	-437	N/A	-540	N/A
12/31/2017	75	-562	N/A	-492	N/A
12/31/2016	29	-504	N/A	-363	N/A

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/07/30 21:50
종가	2026/07/30 00:00
수익	2025/12/31
연간 수익	2025/12/31

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

분석가	기관
Shan He	Bernstein
Rebecca Liang	Bernstein
Bo Li	BofA Global Research

Innovent Biologics 향후 성장

Future 기준 점검 4/6

핵심 정보

최근 향후 성장 업데이트

Recent updates

Innovent Biologics Doses First Patient In Phase 3 Clinical Trial Of IBI3003 For Multiple Myeloma

Innovent Biologics Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity and Metabolic Pipeline

Innovent Biologics Announces IBI343 (Arcotatug Tavatecan) Meets Primary Endpoint In International Phase 3 Study and NDA Accepted By China NMPA

Innovent Presents Preliminary POC Data of IBI363 (Tak-928) Pd-1/Il-2A-Bias Bispecific Fusion Protein) in First-Line Advanced Nsclc

Innovent Biologics' IBI363 (PD-1/IL-2a-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

Innovent Biologics And HUTCHMED Jointly Announce NMPA Approval For TYVYT (Sintilimab Injection) In Combination With ELUNATE (Fruquintinib) For The Treatment Of Patients With Locally Advanced Or Metastatic Renal Cell Carcinoma

Innovent Biologics Announces IBI363 Receives Third NMPA Breakthrough Therapy Designation for Advanced MSS/pMMR Metastatic Colorectal Cancer

Innovent Biologics Announces Pre-Clinical Results of IBI3055, A Tri-Specific T Cell Engager Targeting Autoimmune Diseases

Innovent Biologics, Inc., Annual General Meeting, Jun 24, 2026

Innovent Biologics Announces Phase 3 Registration Star Study of Efdamrofusp Alfa (Ibi302) Meets Primary Endpoint

Innovent Biologics, Inc. Announces First Participant Dosed Of IBI128 Tigulixostat XOI In Phase 3 Clinical Study

Innovent Biologics, Inc. to Report Fiscal Year 2025 Results on Mar 26, 2026

Innovent Biologics, Inc. Announces the Non-Covalent (Reversible) Bruton's Tyrosine Kinase (Btk) Inhibitor, Jaypirca®? (Pirtobrutinib) Receives Approval by the National Medical Products Administration

Innovent Biologics, Inc. Doses First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC ) for First Line Treatment of Her2-Positive Breast Cancer

Innovent Biologics, Inc. Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma

Innovent Biologics, Inc. Announces the Results of Two Phase 3 Clinical Studies of Mazdutide

Innovent Biologics, Inc. Announces Phase 1b Clinical Trial of Mazdutide Injection

Innovent Biologics, Inc. Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody

Innovent Biologics, Inc. Announces Initial Results of the First-In-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

Innovent's Pecondle®? (Picankibart Injection) Receives Nmpa Approval

Innovent Biologics, Inc. Announces the Supplementary Application for the 9 Mg Dose of Mazdutide

Innovent Biologics, Inc. Announces Phase 3 Clinical Trial of Mazdutide

Innovent Biologics, Inc. and Sanegene Bio USA Inc. Announce Phase 1 Clinical Data for IBI3016 Presented at American Heart Association (AHA)2025 Annual Meeting

Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in A Head-To-Head Phase 3 Clinical Trial DREAMS-3

Innovent Announces Mazdutide Receives Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes

Innovent's Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/Ang-2)

Innovent Biologics, Inc. Announces Phase 2 Results of Tigulixostat (Ibi128, Xoi) in Gout Patients Were Published At the 27Th Asia-Pacific League of Associations for Rheumatology Congress

Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (Marslight-11) of Ibi363 (PD-1/IL-2a-bias) in Squamous Non-Small Cell Lung Cancer

Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032

Innovent Biologics, Inc. to Report First Half, 2025 Results on Aug 27, 2025

Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Innovent Biologics, Inc. Receives Approval by the National Medical Products Administration of China for Chronic Weight Management in Chinese Adults

Innovent Biologics, Inc. Announces the Phase 3 Clinical Study Dreams-1 of Mazdutide in China Are Orally Presented At ADA 85th Scientific Sessions

Multiple Research Results from Innovent Biologics, Inc.'s General Biomedicine Pipeline to Be Showcased At the American Diabetes Association's 85Th Scientific Sessions

Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China

The National Medical Products Administration Accepts the New Drug Application for Sintilimab and Fruquintinib for the Treatment of Advanced RCC

Innovent Biologics, Inc. Announces the Third Oral Presentation of Clinical Data for IBI363

Innovent Biologics, Inc. Announces Updated Data of IBI354 (Novel Anti-HER2 ADC) from the Phase 1/2 Clinical Study in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors

Innovent Biologics, Inc. Announces a Phase 3 Study of Picankibart ( Anti-IL-23p19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients with Prior Inadequate Response to Anti-17 Antibodies

Innovent Biologics, Inc. Announces Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (Glory-1) Published in the New England Journal of Medicine

Innovent Biologics, Inc. Announces Second Head-To-head Phase 3 Study of Mazdutide versus Semaglutide Completes First Participant Dosing in Adults in China with Overweight or Obesity Accompanied Fatty Liver Disease (GLORY-3)

Innovent Biologics, Inc. Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302)

Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa

Innovent Biologics, Inc. Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-In-Class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies

Innovent Biologics, Inc. Announces NMPA Approval of Limertinib, a Third-Generation EGFR TKI Collaborated with ASK Pharma, for the First-Line Treatment of Lung Cancer

Innovent Biologics, Inc. Announces Board and Committee Appointments

Innovent Biologics, Inc., Annual General Meeting, Jun 25, 2025

Hutchmed (China) Limited and Innovent Biologics, Inc. Jointly Announce the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab

Innovent Biologics, Inc. Announces China's First IGF-1R Monoclonal Antibody Sycume® Received Approval by the National Medical Products Administration for the Treatment of Thyroid Eye Disease

Innovent Biologics, Inc. to Report Fiscal Year 2024 Results on Mar 26, 2025

Innovent Biologics, Inc. Announces the New Drug Application of Ipilimumab Injection

Innovent Biologics, Inc. and Jiangsu Aosaikang Pharmaceutical Co. Ltd. Jointly Announce NMPA Approval of Limertinib, a Third-Generation EGFR TKI for the Treatment of Lung Cancer

Innovent Biologics, Inc. Announces National Medical Products Administration of China Approves Second New Drug Application of DOVBLERON

Innovent Biologics, Inc. announced that it has received funding from Xuhui Science and Technology Venture Capital

Innovent Biologics, Inc. Receives Approval of DOVBLERON®? (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Innovent Presents Updated Data from Innovative Anti-CLDN18.2 Adc (Ibi343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the Esmo Asia Congress 2024

Innovent Biologics, Inc. Announces First-Time Inclusion of SINTBILO and New Indication for Olverembatinib in China's National Reimbursement Drug List

Innovent Biologics, Inc. Announces Acceptance of New Drug Application for Picankibart Injection by China's NMPA

Innovent Biologics, Inc. Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress

Innovent Biologics, Inc. Announces Change in Composition of Board Committees

Innovent Biologics, Inc. Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China

The National Medical Products Administration Approves Centre for Drug Evaluation of the National Medical Products Administration of China's First KRAS G12C Inhibitor Dupert

Innovent Biologics, Inc. to Report First Half, 2024 Results on Aug 28, 2024

Innovent Biologics, Inc. and Sanegene Bio USA Inc. Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA)

the National Medical Products Administration of China Accepts the New Drug Application of Mazdutide of Innovent Biologics, Inc

Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions

Innovent Biologics, Inc. Announces Picankibart (IBI112) Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA

Innovent Biologics Announces National Medical Products Administration of China Accepts the New Drug Application for IBI311

Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer

Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application

Innovent Biologics, Inc., Annual General Meeting, Jun 21, 2024

Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024

Anheart Therapeutics and Innovent Announces China’s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer